Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.

Laino AS, Betts BC, Veerapathran A, Dolgalev I, Sarnaik A, Quayle SN, Jones SS, Weber JS, Woods DM.

J Immunother Cancer. 2019 Feb 6;7(1):33. doi: 10.1186/s40425-019-0517-0.

2.

Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.

Betts BC, Bastian D, Iamsawat S, Nguyen H, Heinrichs JL, Wu Y, Daenthanasanmak A, Veerapathran A, O'Mahony A, Walton K, Reff J, Horna P, Sagatys EM, Lee MC, Singer J, Chang YJ, Liu C, Pidala J, Anasetti C, Yu XZ.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):1582-1587. doi: 10.1073/pnas.1712452115. Epub 2018 Jan 30.

3.

Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.

Betts BC, Veerapathran A, Pidala J, Yang H, Horna P, Walton K, Cubitt CL, Gunawan S, Lawrence HR, Lawrence NJ, Sebti SM, Anasetti C.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaai8269. doi: 10.1126/scitranslmed.aai8269.

4.

Regulatory T-Cell Therapy for Graft-versus-host Disease.

Heinrichs J, Bastian D, Veerapathran A, Anasetti C, Betts B, Yu XZ.

J Immunol Res Ther. 2016;1(1):1-14. Epub 2016 Apr 28.

5.

HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease.

Li J, Heinrichs J, Haarberg K, Semple K, Veerapathran A, Liu C, Anasetti C, Yu XZ.

J Immunol. 2015 Jul 15;195(2):717-25. doi: 10.4049/jimmunol.1401250. Epub 2015 Jun 5.

6.

Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma.

Locke FL, Menges M, Veerapathran A, Coppola D, Gabrilovich D, Anasetti C.

J Immunother Cancer. 2015 May 19;3:20. doi: 10.1186/s40425-015-0065-1. eCollection 2015.

7.

CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.

Betts BC, Sagatys EM, Veerapathran A, Lloyd MC, Beato F, Lawrence HR, Yue B, Kim J, Sebti SM, Anasetti C, Pidala J.

J Leukoc Biol. 2015 Apr;97(4):807-19. doi: 10.1189/jlb.5A1114-532RR. Epub 2015 Feb 6.

8.

STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity.

Betts BC, Veerapathran A, Pidala J, Yu XZ, Anasetti C.

J Leukoc Biol. 2014 Feb;95(2):205-13. doi: 10.1189/jlb.0313154. Epub 2013 Sep 25.

9.

Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease.

Veerapathran A, Pidala J, Beato F, Betts B, Kim J, Turner JG, Hellerstein MK, Yu XZ, Janssen W, Anasetti C.

Blood. 2013 Sep 26;122(13):2251-61. doi: 10.1182/blood-2013-03-492397. Epub 2013 Aug 1.

10.

A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.

Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C.

Haematologica. 2012 Dec;97(12):1882-9. doi: 10.3324/haematol.2012.067140. Epub 2012 Jun 11.

11.

Cloning and characterization of high mobility group box protein 1 (HMGB1) of Wuchereria bancrofti and Brugia malayi.

Thirugnanam S, Munirathinam G, Veerapathran A, Dakshinamoorthy G, Reddy MV, Ramaswamy K.

Parasitol Res. 2012 Aug;111(2):619-27. doi: 10.1007/s00436-012-2878-x. Epub 2012 Mar 9.

12.

Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly.

Veerapathran A, Pidala J, Beato F, Yu XZ, Anasetti C.

Blood. 2011 Nov 17;118(20):5671-80. doi: 10.1182/blood-2011-02-337097. Epub 2011 Sep 23.

13.

Evaluation of Wuchereria bancrofti GST as a vaccine candidate for lymphatic filariasis.

Veerapathran A, Dakshinamoorthy G, Gnanasekar M, Reddy MV, Kalyanasundaram R.

PLoS Negl Trop Dis. 2009 Jun 9;3(6):e457. doi: 10.1371/journal.pntd.0000457.

14.

T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data.

Veerapathran A, Joshi R, Goswami K, Dogra S, Moodie EE, Reddy MV, Kalantri S, Schwartzman K, Behr MA, Menzies D, Pai M.

PLoS One. 2008 Mar 26;3(3):e1850. doi: 10.1371/journal.pone.0001850.

Supplemental Content

Loading ...
Support Center